PROCEPT BioRobotics Corp. to Present at 11th Annual SVB Leerink Global Healthcare Conference and Cowen’s 42nd Annual Health Care Conference

Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced its upcoming participation in two major investor conferences. The first is the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 2:00 pm PT / 5:00 pm ET, followed by the 42nd Annual Cowen Health Care Conference on March 9, 2022, at 9:50 am PT / 12:50 pm ET. A live webcast and archive will be accessible on the company's website for 90 days post-event. PROCEPT specializes in robotic solutions for urology, particularly the AquaBeam Robotic System, addressing benign prostatic hyperplasia (BPH), impacting around 40 million men in the U.S.

REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present virtually at the following two investor conferences:

• 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th, 2022, at 2:00 pm Pacific Time / 5:00 pm Eastern Time
  
  
• 42^nd Annual Cowen Health Care Conference on Wednesday, March 9th, 2022, at 9:50 am Pacific Time / 12:50 pm Eastern Time
  

A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Gilmartin Group
Matt Bacso, CFA
Matt.bacso@gilmartinir.com 

FAQ

What conferences will PROCEPT BioRobotics attend in February 2022?

PROCEPT BioRobotics will attend the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, and the 42nd Annual Cowen Health Care Conference on March 9, 2022.

What is the purpose of PROCEPT BioRobotics' participation in these conferences?

The purpose is to present their innovative surgical robotics solutions and advancements in urology, specifically their AquaBeam Robotic System.

How can I access the webcasts of the conferences featuring PROCEPT BioRobotics?

The webcasts for the conferences will be available on the company's website in the 'Investors' section and will be archived for at least 90 days.

What is the AquaBeam Robotic System developed by PROCEPT BioRobotics?

The AquaBeam Robotic System is an advanced, image-guided surgical system designed for minimally-invasive urologic surgery, specifically treating benign prostatic hyperplasia (BPH).

How many men in the United States are affected by BPH?

Approximately 40 million men in the United States are impacted by benign prostatic hyperplasia (BPH).